API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. E75 Her2 Peptide
2. Her2 (369-377)
3. Her2 Peptide (369-377)
4. Nelipepimut-5
1. Kifgslafl
2. 160212-35-1
3. Neuvax
4. Neuvax Vaccine
5. L-lysyl-l-isoleucyl-l-phenylalanylglycyl-l-seryl-l-leucyl-l-alanyl-l-phenylalanyl-l-leucine
6. Nelipepimut-s [usan]
7. Unii-7m0a29cd8b
8. E75 Peptide
9. 7m0a29cd8b
10. Chembl386200
11. Dtxsid80166835
12. Bdbm50409332
13. E-75
14. Her-2(369-377)
15. Hy-106204
16. Cs-0025241
17. Q27268544
18. (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic Acid
19. Human Receptor Tyrosine-protein Kinase Erbb-2 (proto-oncogene Neu, Tyrosine Kinase- Type Cell Surface Receptor Her2, Cd340)-(347-355)-peptide
Molecular Weight | 995.2 g/mol |
---|---|
Molecular Formula | C50H78N10O11 |
XLogP3 | 0.4 |
Hydrogen Bond Donor Count | 12 |
Hydrogen Bond Acceptor Count | 13 |
Rotatable Bond Count | 32 |
Exact Mass | 994.58515334 g/mol |
Monoisotopic Mass | 994.58515334 g/mol |
Topological Polar Surface Area | 342 Ų |
Heavy Atom Count | 71 |
Formal Charge | 0 |
Complexity | 1720 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 9 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in prostate cancer and breast cancer.
NeuVax is a HER2/neu peptide-based T-cell immunotherapy aimed at preventing disease recurrence and prolonging survival in cancer patients that have tumors which express the HER2/neu oncoprotein. To date, clinical study results have demonstrated that NeuVax significantly reduces the rate of cancer recurrence while showing minimal side effects. [Apthera Press release]